| HOPE FOR FIBROIDS | ||||||||||||||||||||||||
|
|
Note:
2007 AAGL meeting, Las Vegas, Nevada
The ExAblate staff consisted of the following:
The patient's Gynecologist, MRI technician, two nurses, an ExAblate
physician and a representative from InSightec who was training the site.
The first phase was acquiring the MRI images for the treatment, shaving
any hair from the abdominal and pubic areas, preparing the patient for a
Foley catheter to regulate fluid in the bladder, inserting an IV that the
anesthesiologist uses to administer conscious sedation, preparing the
ExAblate patient table, and positioning the woman face down on the table
with her head facing the technician booth.
A stop button was available for the patient so that in the event she experienced pain the treatment would be immediately stopped and her condition assessed. (If the patient feels pain/discomfort, unusual warmth where the treatment beam is being directed, or sensations radiating from the treatment site it is VERY IMPORTANT that she tells the doctor immediately what she is experiencing so the doctor(s) can decide if the procedure should be stopped.) During the entire session the patient must lie still because the Focused Ultrasound beam has a precise location it is being directed to and any movement could cause the Focused Ultrasound energy to be misdirected. Due to the size and location of the fibroids in this patient a full bladder fill was required to move the organs out of the way so the fibroid could be treated. Sometimes the rectum must be filled with air to move the intestines out of the MRI energy sonications path. On the screen the area was marked around the fibroid to show if the patient was moving. The Focused Ultrasound energy pulses were aimed directly into the marked middle area of the fibroid. Immediately after the procedure the results can be monitored in real time with MRI images showing the heat change that occurred within the fibroid tissue and this gives the doctors the ability to see the coagulation necrosis (death) process of the fibroid. The success as measured by “non perfused volume” was 80% for this specific case. After the procedure the patient rested for approximately 30 minutes while the medication wore off and then went home.
We asked
Richard Chudacoff, MD, Arthur Chan, Ph.D., and Bernard Cantor, MD to
explain the ExAblate procedure in more detail.
The medical information for the four (4) procedures that were performed on November 7-8, 2006:
All fibroids treated had non perfused volumes of 60%-100% (no blood flowed through 60-100% of each of the fibroids, which indicates that 60-100% of each fibroid was dead).
-
In general, a woman would be a candidate for MR Guided Focused Ultrasound (Exablate) if: 1) You have one or a few large fibroids rather than many small ones that are causing symptoms such as heavy bleeding, pain, or abdominal enlargement. 2) The fibroids are located in the body of the uterus-not on a stalk (pedunculated) 3) You have not had multiple abdominal surgeries that may result in bowel being adherent to the front of the uterus. 4) Your family is complete-this procedure is not FDA approved for women who contemplate becoming pregnant in the future. 5) You weigh less than 250 lbs and can lie comfortably on your abdomen for up to 3 hours. 6) You have no contraindications for MRI such as an implanted metal device (pacemaker, artificial joint, etc.). ExAblate And Uterine Fibroids SeminarOn Wednesday, November 8th, Dr. Richard Gimpelson, AAGL President, was the Moderator for the ExAblate meeting. The Speakers for this event were Dr. Richard Chudacoff, Dr. Elizabeth Stewart, and Mr. Chuck Cohen. Dr. Chudacoff, Gynecologist from Houston, Texas, was one of the first gynecologists to perform the ExAblate procedure. Dr. Stewart, Brigham and Women’s Hospital, performs the ExAblate procedure and handles some of the clinical research. Mr. Cohen, President and CEO Sound Medical Solutions, partners with gynecologists to set up and operate ExAblate centers around the country. The topics covered at the meeting: - How MR guided Focused Ultrasound Surgery works – Dr. Chudacoff - MRgFUS clinical results and new developments – Dr. Stewart - Incorporating MRgFUS into your office based Ob/Gyn practice - Mr. Cohen -Questions and Answers - Faculty Some research updates that were mentioned at the meeting:
-Twenty-three (23 babies, 21 women) were born after having the ExAblate
procedure. - The magnetic resonance-guided focused ultrasound research is in a number of areas such as breast, bone, prostate, liver, and brain tumors. - November 7, 2006, the U.S. Food and Drug Administration (FDA) announced the ExAblate 2000 system as one of 14 medically significant products it approved during fiscal 2005. Website URL: www.fda.gov/cdrh/annual/fy2005/ode/part1.html - In 2006, nine (9) Centers were opened for Gyns. The nine sites include the Deployed Medical Solutions sites plus the sites in Houston, Chicago, and Seattle. - Twenty (20) ExAblate Centers are in the process of being scheduled for 2007. After the speakers presentation the audience was allowed to ask the panel of experts questions. Several doctors from around the world discussed their experiences and concerns about the procedure.
The AAGL meeting covered an enormous amount of gynecological subjects. To find more of the 2007 AAGL Conference topics, photos, and seminar information please refer to www.obgyn.net.
|
|
||||||||||||||||||||||